After-Hours Movers 12/17: (SCS) (CTAS) (NE) Higher; (FIXX) (PACB) (FDX) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cintas (CTAS) PT Raised to $294 at BofA Securities
December 18, 2019 8:47 AM ESTBofA Securities analyst Gary Bisbee raised the price target on Cintas (NASDAQ: CTAS) to $294.00 (from $291.00) while maintaining a Buy rating following results.
Solid Q2 beat and raise, though Rentals slows modestly... MoreNeoleukin Therapeutics (NLTX) Prices 8.925M Share Offering at $8.40/Sh
December 18, 2019 6:09 AM ESTNeoleukin Therapeutics, Inc. (Neoleukin) (NASDAQ: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the pricing of an underwritten public offering of 8,925,000 shares of its common stock at a price to the public of $8.40 per share. The... More
